Sandoz's biosimilar will be sold under the trade name Zarxio but the FDA has held off on releasing a naming policy for biosimilars, giving the product a "placeholder nonproprietary name" of "filgrastim-sndz."
Earlier this month, the FDA announced the first approval of a biosimilar product under the Biologics Price Competition and Innovation Act (BPCIA). The new Sandoz product, which will be sold under the trade name Zarxio, is a biosimilar of Amgen’s Neupogen (filgrastim) product. The FDA has, however, held off on releasing a naming policy for biosimilars, giving the product a “placeholder nonproprietary name” of “filgrastim-sndz.”
The FDA has stated that this placeholder name “should not be viewed as reflective of the agency’s decision on a comprehensive naming policy for biosimilar and other biological products” and that the agency intends to issue naming guidance in the “near future.”
Read more at Biologics Blog: http://bit.ly/1FycpNd
AD Progression Adversely Influenced by Outdoor Air Pollution
February 2nd 2023With atopic dermatitis (AD) prevalence increasing around the world, primarily in developing countries, investigators evaluated the potential for pollution to have an impact on development of the chronic skin condition among an adult population.
Read More
Promoting Health Equity and Resiliency in Trauma-Affected Communities
January 31st 2023On this episode of Managed Care Cast, we speak with Reverend Paul Abernathy, CEO of the Neighborhood Resilience Project and board member of UPMC for You, who discusses his experiences in promoting health and resiliency in trauma-affected communities, as well as challenges related to access and accessibility of care and medical mistrust.
Listen
Merck & Co. and Eli Lilly & Co. report sales loss for COVID-19 treatments; Republican state attorneys general tell CVS and Walgreens that mailing mifepristone might break the law; exposure to air pollution over time is associated with a rise in incidence of depression and anxiety.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
Periostin Bests Eosinophil Count for Biomarker Predictability in ECRS
February 2nd 2023Known to be a contributing factor to polyp development at high levels, periostin’s potential as a biomarker for eosinophilic chronic rhinosinusitis (ECRS) severity was investigated in a new study in which outcomes were compared between patients who had ECRS and those with non-ECRS.
Read More
2 Clarke Drive
Cranbury, NJ 08512